Murine cytomegalovirus was utilized as a model for human cytomeglovirus, which had no experimental animal, to study immunoprophylaxis of the cytomegalovirus infections.( 1) Murine cytomegalovirus (MCMV) serially propagated in mouse embryonic fibroblasts had lost pathogenicity for weanling mice including neonatally thymectomized mice.(2) The cell culture-adapted MCMV was effective as a "live, attenuated virus vaccine" against challenge by virulent, mouse-passaged MCMV.(3) The immunization via intraperitoneal route protected mice from every parameter of MCMV infection. These included clinical signs, virus replication, histopathology and mortality.(4) The protective immunity was active against the virulent MCMV which was not neutralized by the rabbit anti-attenuated MCMV serum.Cytomegalovirus (CMV), a member of the Herpetoviridae, is ubiquitous in human population. It has been reported that approximately 1 % of the newborns are infected by human CMV and at least 10% of the infected neonates suffer damage to the central nervous system (3,5,11,14). These facts have drawn much attention to development of CMV vaccines (2, 9, 10). However, since the human CMV is highly species-specific and has no experimental animal, pathogenicity of the CMV and immunity to the CMV infection have remained poorly understood.To solve this problem, we have employed murine CMV (MCMV) (7) which simulates the human CMV with regard to pattern of infection, except for transplacental infection (4). In addition, since the MCMV is attenuated by in vitro passages and the attenuated MCMV is immunogenic for mice (8), the MCMV system is expected to provide a model for immunoprophylaxis of the CMV infection in human (6). This paper is concerned with effect of prior immunization with a live attenuated MCMV (CC-MCMV) on mortality, clinical signs, virus replication, and histopathological changes in mice subsequently challenged with a virulent MCMV (SG-MCMV).693